| 2026-08-10 | 8-K | 10.2 | Amendment No. 4 to Term Loan Credit Agreement by and among Amneal LLC, certain of Amneal LLC’s subsidiaries, as guarantors, the Lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent. |
|---|
| 2026-08-10 | 8-K | 10.1 | First Amendment to the Third Amended and Restated Stockholders Agreement by and among Amneal, Amneal Intermediate Inc., Amneal LLC, and the other parties named therein. |
|---|
| 2026-08-03 | 8-K | 10.1 | Amendment No. 3 to Term Loan Credit Agreement, dated as of August 3, 2026, by and among Amneal Pharmaceuticals LLC, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent. |
|---|
| 2026-04-22 | 8-K | 10.2 | Restrictive Covenants Agreement by and between Amneal Pharmaceuticals, Inc. and Chintu Patel, dated as of April 21, 2026. |
|---|
| 2026-04-22 | 8-K | 10.1 | Restrictive Covenants Agreement by and between Amneal Pharmaceuticals, Inc. and Chirag Patel, dated as of April 21, 2026. |
|---|
| 2026-02-27 | 10-K | 10.14 | Amneal Pharmaceuticals, Inc. 2018 Incentive Award Plan Performance Restricted Stock Unit Grant Notice.* † |
|---|
| 2026-02-03 | 8-K | 10.1 | Amendment No. 2 to Term Loan Credit Agreement, dated as of February 2, 2026, by and among Amneal Pharmaceuticals LLC, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent. |
|---|
| 2025-08-07 | 10-Q | 10.5 | Amended and Restated Revolving Credit and Term Loan Agreement, dated April 9, 2025, by and among Rondo Intermediate Holdings and LLC and Rondo Holdings, LLC, several banks and other financial institutions and lenders from time to time party hereto and Trust Bank, in its capacity as administrative agent for the Lenders and the Issuing bank.* |
|---|
| 2025-08-07 | 10-Q | 10.4 | Amneal Pharmaceuticals LLC Severance Plan and Summary Plan Description amended and restated effective May 1, 2025.* † |
|---|
| 2025-08-07 | 10-Q | 10.3 | Modification No. 3 to Employment Agreement, dated March 11, 2020, by and among Amneal Pharmaceuticals, Inc. and Anastasios (Tasos) G. Konidaris, dated April 1, 2025.* † |
|---|
| 2025-08-07 | 10-Q | 10.2 | Modification No. 3 to Employment Agreement, dated February 6, 2018, by and among Amneal Pharmaceuticals, Inc. and Andrew Boyer, dated April 1, 2025.* † |
|---|
| 2025-08-07 | 10-Q | 10.1 | Modification No. 2 to Employment Agreement, dated July 29, 2020, by and among Amneal Pharmaceuticals, Inc. and Nikita Shah, dated April 1, 2025.* † |
|---|
| 2025-08-01 | 8-K | 10.2 | Amendment No. 2 to Revolving Credit Agreement and Amendment No. 2 to Collateral Agreement, dated as of August 1, 2025, by and among Amneal Pharmaceuticals LLC, the other loan parties party hereto, the lenders party hereto and Truist Bank, as administrative agent and collateral agent. |
|---|
| 2025-08-01 | 8-K | 10.1 | Amendment No. 1 to Term Loan Credit Agreement and Amendment No. 1 to Collateral Agreement, dated as of August 1, 2025, by and among Amneal Pharmaceuticals LLC, the lenders party thereto, JPMorgan Chase Bank, NA., as administrative agent and collateral agent, and the bookrunners and arrangers party thereto. |
|---|
| 2025-05-07 | 10-Q | 10.1 | Employment Agreement, dated March 1, 2025, by and among Amneal Pharmaceuticals, Inc. and Jason Daly.†* |
|---|
| 2025-02-28 | 10-K | 10.14 | Amneal Pharmaceuticals, Inc. 2018 Incentive Award Plan Performance Restricted Stock Unit Grant Notice.* † |
|---|
| 2023-11-14 | 8-K | 10.3 | Amendment No. 1 to the Revolving Credit Agreement and Amendment No. 1 to the Collateral Agreement, dated November 14, 2023, by and among Amneal Pharmaceuticals LLC, the lenders party thereto from time to time and Truist Bank as administrative agent and collateral agent. |
|---|
| 2023-11-14 | 8-K | 10.2 | Term Loan Credit Agreement, dated as of November 14, 2023, by and among Amneal Pharmaceuticals LLC, the lenders party thereto, J.P. Morgan Chase Bank, N.A. as administrative agent and collateral agent. |
|---|
| 2023-11-14 | 8-K | 10.1 | Amendment No. 2 to Term Loan Credit Agreement, dated as of November 14, 2023, among Amneal Pharmaceuticals LLC, each of the lenders party thereto, and J.P. Morgan Chase Bank, N.A. as administrative agent and collateral agent. |
|---|
| 2023-11-09 | 10-Q | 10.3 | Amendment No. 2 Revolving Credit and Term Loan Agreement, dated as of September 21, 2023, by and among Rondo Holdings, LLC, Rondo Intermediate Holdings, LLC, the Subsidiary Loan Parties party hereto, the Lenders party hereto and Truist Bank as Administrative Agent.* |
|---|
| 2023-11-09 | 10-Q | 10.2 | Amendment No. 1 to Revolving Credit and Term Loan Agreement, dated as of April 20, 2023, by and among Rondo Holdings, LLC, Rondo Intermediate Holdings, LLC, the Subsidiary Loan Parties party hereto, the Lenders party hereto and Truist Bank as Administrative Agent (correcting Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed on August 8, 2023, to include Annexes).* |
|---|
| 2023-11-09 | 10-Q | 10.1 | Amendment No. 1 to Term Loan Credit Agreement, dated as of May 30, 2023, entered into by and among Amneal Pharmaceuticals LLC, the Guarantors, and JPMorgan Chase Bank, N.A. as administrative agent (correcting Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed on August 8, 2023, to include Annexes).* |
|---|
| 2023-10-17 | 8-K | 10.1 | Term Sheet, dated as of October 16, 2023 among, the Company, Amneal Pharmaceuticals LLC and the Amneal Group Representative. |
|---|
| 2023-08-08 | 10-Q | 10.3 | Amendment No.1 to Revolving Credit and Term Loan Agreement, dated as of April 20, 2023, by and among Rondo Holdings, LLC, Rondo Intermediate Holdings, LLC, the Subsidiary Loan Parties party hereto, the Lenders party hereto and Truist Bank as Administrative Agent.* |
|---|
| 2023-08-08 | 10-Q | 10.2 | Amendment No. 1 to Term Loan Credit Agreement, dated as of May 30, 2023, entered into by and among Amneal Pharmaceuticals LLC, the Guarantors, and JPMorgan Chase Bank, N.A. as administrative agent.* |
|---|
| 2023-08-08 | 10-Q | 10.1 | Amneal Pharmaceuticals, Inc. 2018 Incentive Award Plan, as amended and restated.*† |
|---|
| 2023-05-09 | 10-Q | 10.3 | Modification No. 2 to Employment Agreement, dated February 21, 2023, by and among Amneal Pharmaceuticals, Inc. and Andrew Boyer. †* |
|---|
| 2023-05-09 | 10-Q | 10.2 | Modification No. 1 to Employment Agreement, dated February 21, 2023, by and among Amneal Pharmaceuticals, Inc. and Nikita Shah. †* |
|---|
| 2023-05-09 | 10-Q | 10.1 | Modification No. 2 to Employment Agreement, dated February 21, 2023, by and among Amneal Pharmaceuticals, Inc. and Anastasios Konidaris. †* |
|---|
| 2022-09-06 | 8-K | 10.1 | Employment Agreement dated September 1, 2022, by and between Amneal Pharmaceuticals, Inc. and Gustavo Pesquin. |
|---|
| 2022-08-08 | 10-Q | 10.1 | Amneal Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended on August 4, 2022 †* |
|---|
| 2022-06-02 | 8-K | 10.2 | ABL Guarantee and Collateral Agreement, dated as of June 2, 2022, by and among the loan parties from time-to-time party thereto and Truist Bank, as administrative agent and collateral agent. |
|---|
| 2022-06-02 | 8-K | 10.1 | Revolving Credit Agreement, dated as of June 2, 2022, by and among Amneal Pharmaceuticals LLC, as the borrower, Truist Bank, as administrative agent and collateral agent and the lenders and other parties party thereto. |
|---|
| 2021-08-09 | 10-Q | 10.1 | Amneal Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended and restated on May 5, 2021. †* |
|---|
| 2021-05-07 | 10-Q | 10.2 | Employment Agreement by and among Amneal Pharmaceuticals, Inc. and Nikita Shah, dated as of July 29, 2020. †* |
|---|
| 2021-05-07 | 10-Q | 10.1 | Employment Agreement by and among Amneal Pharmaceuticals, Inc. and Joseph Todisco, dated as of July 29, 2020. †* |
|---|
| 2021-03-01 | 10-K | 10.13 | Amneal Pharmaceuticals, Inc. Non- Employee Director Compensation Policy.†* |
|---|
| 2021-03-01 | 10-K | 10.12 | Form of Amneal Pharmaceuticals, Inc. 2018 Incentive Award Plan Performance Restricted Stock Unit Grant Notice and Performance Restricted Stock Unit Agreement (2020).†* |
|---|
| 2020-11-06 | 10-Q | 10.1 | Modification No. 1 to Employment Agreement, effective as of August 1, 2020, by and among Amneal Pharmaceuticals LLC, Amneal Holdings, LLC and Andrew Boyer * † |
|---|
| 2020-08-06 | 10-Q | 10.1 | Amneal Pharmaceuticals LLC Severance Plan and Summary Plan Description |
|---|
| 2020-05-11 | 10-Q | 10.6 | Form of Amneal Pharmaceuticals, Inc. 2018 Incentive Plan Performance Restricted Stock Unit Grant Notice and Performance Restricted Stock Unit Agreement. † |
|---|
| 2020-05-11 | 10-Q | 10.4 | First Amendment to Separation Agreement between David Buchen, Amneal Pharmaceuticals, Inc. and Amneal Pharmaceuticals LLC, dated as of November 4, 2019. † |
|---|
| 2020-05-11 | 10-Q | 10.3 | Separation Agreement between David Buchen, Amneal Pharmaceuticals, Inc. and Amneal Pharmaceuticals LLC, dated as of August 2, 2019. † |
|---|
| 2020-05-11 | 10-Q | 10.2 | Employment Agreement by and among Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals, Inc. and David Buchen, dated as of December 28, 2018. † |
|---|
| 2020-05-11 | 10-Q | 10.1 | Separation Agreement between Todd Branning, Amneal Pharmaceuticals, Inc. and Amneal Pharmaceuticals LLC, dated as of March 11, 2020 † |
|---|
| 2020-03-12 | 8-K | 10.1 | Employment Agreement, dated March 11, 2020, by and among Amneal Pharmaceuticals LLC, the Company and Anastasios (Tasos) G. Konidaris |
|---|
| 2020-03-02 | 10-K | 10.12 | Amneal Pharmaceuticals, Inc. Non-Employee Director Compensation Policy.* † |
|---|
| 2019-08-05 | 10-Q | 10.5 | Amendment No. 1, dated as of August 2, 2019, to Second Amended and Restated Stockholders Agreement, by and among Amneal Pharmaceuticals Holding Company, LLC, a Delaware limited liability company, AP Class D Member, LLC, a Delaware limited liability company, AP Class E Member, LLC, a Delaware limited liability company, AH PPU Management, LLC, a Delaware limited liability company, and Amneal Pharmaceuticals, Inc. † |
|---|
| 2019-08-05 | 10-Q | 10.4 | Separation Agreement between Robert Stewart, Amneal Pharmaceuticals, Inc. and Amneal Pharmaceuticals LLC, dated as of August 2, 2019 *† |
|---|
| 2019-08-05 | 10-Q | 10.3 | Form of Tripartite Acknowledgment and Agreement Morgan Stanley* |
|---|
| 2019-08-05 | 10-Q | 10.2 | Form of Tripartite Letter Agreement Credit Suisse* |
|---|
| 2019-05-09 | 8-K | 10.1 | 2019 SEVERANCE PLAN |
|---|
| 2019-03-01 | 10-K | 10.19 | Separation Agreement, dated February 28, 2019, by and between Bryan Reasons and Amneal Pharmaceuticals, Inc.* † |
|---|
| 2019-03-01 | 10-K | 10.18 | Separation Agreement, dated February 5, 2019, by and between Sheldon Hirt and Amneal Pharmaceuticals, Inc.* † |
|---|
| 2019-03-01 | 10-K | 10.11 | Form of Amneal Pharmaceuticals, Inc. 2018 Incentive Award Plan Performance Restricted Stock Unit Grant Notice and Performance Restricted Stock Unit Agreement.* † |
|---|
| 2019-03-01 | 10-K | 10.5.1 | Amendment No. 1 to Third Amended and Restated Limited Liability Company Agreement of Amneal Pharmaceuticals LLC, dated as of February 14, 2019, with effect as of May 4, 2018.* |
|---|
| 2019-01-24 | 8-K | 10.1 | EXHIBIT 10.1 - BRANNING EMPLOYMENT AGREEMENT |
|---|
| 2018-08-09 | 10-Q | 10.8 | Amneal Pharmaceuticals, Inc. 2018 Incentive Award Plan.* † |
|---|
| 2018-05-07 | 8-K | 10.14 | Amneal Pharmaceuticals LLC Severance Plan and Summary Plan Description |
|---|
| 2018-05-07 | 8-K | 10.13 | Unsecured Promissory Note, dated as of May 7, 2018, issued by Amneal Pharmaceuticals LLC to the Sellers (as defined therein). |
|---|
| 2018-05-07 | 8-K | 10.12 | Employment Agreement, dated May 4, 2018, by and between Amneal Pharmaceuticals, Inc. and Paul M. Bisaro. |
|---|
| 2018-05-07 | 8-K | 10.11 | Form of Amneal Pharmaceuticals, Inc. Non-Employee Director Compensation Policy. |
|---|
| 2018-05-07 | 8-K | 10.10 | Form of Amneal Pharmaceuticals, Inc. 2018 Incentive Award Plan Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement. |
|---|
| 2018-05-07 | 8-K | 10.9 | Form of Amneal Pharmaceuticals, Inc. 2018 Incentive Award Plan Stock Option Grant Notice and Stock Option Agreement. |
|---|
| 2018-05-07 | 8-K | 10.7 | Form of Indemnification and Advancement Agreement. |
|---|
| 2018-05-07 | 8-K | 10.6 | Tax Receivable Agreement, dated as of May 4, 2018, by and among Amneal Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC and the Members of Amneal Pharmaceuticals LLC from time to time party thereto. |
|---|
| 2018-05-07 | 8-K | 10.5 | Third Amended and Restated Limited Liability Company Agreement, adopted as of May 4, 2018. |
|---|
| 2018-05-07 | 8-K | 10.4 | Revolving Loan Guarantee and Collateral Agreement, dated as of May 4, 2018, by and among the loan parties from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent. |
|---|
| 2018-05-07 | 8-K | 10.3 | Term Loan Guarantee and Collateral Agreement, dated as of May 4, 2018, by and among the loan parties from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent. |
|---|
| 2018-05-07 | 8-K | 10.2 | Revolving Credit Agreement, dated as of May 4, 2018, by and among Amneal Pharmaceuticals LLC, as the borrower, the other loan parties from time to time party thereto, JPMorgan Chase Bank, N.A., as administrative agent and collateral agent and the lenders and other parties party thereto. |
|---|
| 2018-05-07 | 8-K | 10.1 | Term Loan Credit Agreement, dated as of May 4, 2018, by and among Amneal Pharmaceuticals LLC, as the borrower, JPMorgan Chase Bank, N.A., as administrative agent and collateral agent, and the lenders and other parties party thereto. |
|---|